



IBA Highlights the Future of Proton Therapy Technologies and the power of its network of partners at ASTRO 2020 Annual Meeting

IBA showcases how its Proteus solutions and its network of clinical and industrial partners are shaping the future of proton therapy

Louvain-la-Neuve, Belgium, October 23, 2020 – IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions, will highlight how its Proteus solutions as well as its work with its partners are shaping the future of proton therapy during the Annual Meeting and exhibition of the American Society for Radiation Oncology (ASTRO) being held online from October 23-29, 2020.

IBA is displaying the latest developments for its Proteus systems that will address the current and future needs of proton Therapy centers. IBA's comprehensive Motion Management package will help clinicians treat more indications more confidently. Additionally, IBA's unique Proton Arc Therapy¹ will enable clinicians to treat patients precisely, faster and more easily. Finally, IBA believes Flash Therapy¹ using protons has the potential to radically change the radiation therapy landscape revolutionize cancer care in general.

With 59 centers sold and 36 centers treating patients on a daily basis, IBA has the largest and most knowledgeable proton therapy user community. Together with its clinical partners, IBA is proud to celebrate a truly significant milestone of over 100,000 patients treated on an IBA Proteus system. This unique accumulated technical and clinical expertise is openly shared within IBA's network of users through regular User Meetings, bringing together experienced users as well as new members in the IBA community.

Having an Open Vendor Platform, IBA also integrates the solutions of key leading industrial partners to further improve clinical workflow, integration and the overall user experience.

IBA has a long-term collaboration with Philips in imaging, diagnostics and radiation therapy for more advanced and comprehensive cancer treatment.

The long-standing collaboration with Elekta is allowing both companies to offer a full set of treatment modalities in radiation therapy. IBA is very excited about the upcoming innovations in the Elekta Treatment Planning Solution. Together with MOSAIQ[®] OIS and MOSAIQ[®] Plaza, this complete solution will provide a strong ecosystem to integrate Proton Therapy into radiation therapy departments.

Close collaboration with RaySearch Laboratories has demonstrated a fully integrated proton therapy workflow integrating IBA's Proteus solution with advanced treatment planning system (TPS)



RayStation^{®2} and next-generation oncology information system (OIS) RayCare^{®2} an at the University hospital of Leuven in Belgium, where patient treatments began in July.

Olivier Legrain, Chief Executive Officer of IBA commented: “We are immensely proud that IBA’s technology has now impacted over 100,000 lives, giving patients and their families a new hope for the future. We continue to pursue further innovation by developing new technologies that will allow us to provide increasingly high standards while reducing treatment costs. Our philosophy of openly sharing our technological expertise with our clinical and industrial partners makes us uniquely positioned to speed up the development and shape the future of proton therapy.”

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com

¹ Arc Therapy is work in progress and Flash Therapy is currently under research. They are not available for sale.

² Subject to regulatory clearance in some markets

For further information, please contact:

IBA

Aymeric Harmant

Global Marketing Director

+32 10 203 796

global.marketing@iba-group.com